BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

218 related articles for article (PubMed ID: 11136714)

  • 1. A germline deletion of p14(ARF) but not CDKN2A in a melanoma-neural system tumour syndrome family.
    Randerson-Moor JA; Harland M; Williams S; Cuthbert-Heavens D; Sheridan E; Aveyard J; Sibley K; Whitaker L; Knowles M; Bishop JN; Bishop DT
    Hum Mol Genet; 2001 Jan; 10(1):55-62. PubMed ID: 11136714
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comprehensive analysis of CDKN2A (p16INK4A/p14ARF) and CDKN2B genes in 53 melanoma index cases considered to be at heightened risk of melanoma.
    Laud K; Marian C; Avril MF; Barrois M; Chompret A; Goldstein AM; Tucker MA; Clark PA; Peters G; Chaudru V; Demenais F; Spatz A; Smith MW; Lenoir GM; Bressac-de Paillerets B;
    J Med Genet; 2006 Jan; 43(1):39-47. PubMed ID: 15937071
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Alterations of the tumor suppressor genes CDKN2A (p16(INK4a)), p14(ARF), CDKN2B (p15(INK4b)), and CDKN2C (p18(INK4c)) in atypical and anaplastic meningiomas.
    Boström J; Meyer-Puttlitz B; Wolter M; Blaschke B; Weber RG; Lichter P; Ichimura K; Collins VP; Reifenberger G
    Am J Pathol; 2001 Aug; 159(2):661-9. PubMed ID: 11485924
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Characterization of a germ-line deletion, including the entire INK4/ARF locus, in a melanoma-neural system tumor family: identification of ANRIL, an antisense noncoding RNA whose expression coclusters with ARF.
    Pasmant E; Laurendeau I; Héron D; Vidaud M; Vidaud D; Bièche I
    Cancer Res; 2007 Apr; 67(8):3963-9. PubMed ID: 17440112
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A novel type of deletion in the CDKN2A gene identified in a melanoma-prone family.
    Knappskog S; Geisler J; Arnesen T; Lillehaug JR; Lønning PE
    Genes Chromosomes Cancer; 2006 Dec; 45(12):1155-63. PubMed ID: 17001621
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Germline mutation of ARF in a melanoma kindred.
    Hewitt C; Lee Wu C; Evans G; Howell A; Elles RG; Jordan R; Sloan P; Read AP; Thakker N
    Hum Mol Genet; 2002 May; 11(11):1273-9. PubMed ID: 12019208
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Fine-mapping loss of gene architecture at the CDKN2B (p15INK4b), CDKN2A (p14ARF, p16INK4a), and MTAP genes in head and neck squamous cell carcinoma.
    Worsham MJ; Chen KM; Tiwari N; Pals G; Schouten JP; Sethi S; Benninger MS
    Arch Otolaryngol Head Neck Surg; 2006 Apr; 132(4):409-15. PubMed ID: 16618910
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Screening of germline mutations in the CDKN2A and CDKN2B genes in Swedish families with hereditary cutaneous melanoma.
    Platz A; Hansson J; Månsson-Brahme E; Lagerlof B; Linder S; Lundqvist E; Sevigny P; Inganäs M; Ringborg U
    J Natl Cancer Inst; 1997 May; 89(10):697-702. PubMed ID: 9168184
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Functional evidence for a role of combined CDKN2A (p16-p14(ARF))/CDKN2B (p15) gene inactivation in malignant gliomas.
    Simon M; Köster G; Menon AG; Schramm J
    Acta Neuropathol; 1999 Nov; 98(5):444-52. PubMed ID: 10541865
    [TBL] [Abstract][Full Text] [Related]  

  • 10. CDKN2A germline splicing mutation affecting both p16(ink4) and p14(arf) RNA processing in a melanoma/neurofibroma kindred.
    Petronzelli F; Sollima D; Coppola G; Martini-Neri ME; Neri G; Genuardi M
    Genes Chromosomes Cancer; 2001 Aug; 31(4):398-401. PubMed ID: 11433531
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Genetic status of cell cycle regulators in squamous cell carcinoma of the oesophagus: the CDKN2A (p16(INK4a) and p14(ARF) ) and p53 genes are major targets for inactivation.
    Smeds J; Berggren P; Ma X; Xu Z; Hemminki K; Kumar R
    Carcinogenesis; 2002 Apr; 23(4):645-55. PubMed ID: 11960918
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The contribution of large genomic deletions at the CDKN2A locus to the burden of familial melanoma.
    Lesueur F; de Lichy M; Barrois M; Durand G; Bombled J; Avril MF; Chompret A; Boitier F; Lenoir GM; ; Bressac-de Paillerets B; Baccard M; Bachollet B; Berthet P; Bonadona V; Bonnetblanc JM; Caron O; Chevrant-Breton J; Cuny JF; Dalle S; Delaunay M; Demange L; De Quatrebarbes J; Doré JF; Frénay M; Fricker JP; Gauthier-Villars M; Gesta P; Giraud S; Gorry P; Grange F; Green A; Huiart L; Janin N; Joly P; Kérob D; Lasset C; Leroux D; Limacher JM; Longy M; Mansard S; Marrou K; Martin-Denavit T; Mateus C; Maubec E; Olivier-Faivre L; Orlandini V; Pujol P; Sassolas B; Stoppa-Lyonnet D; Thomas L; Vabres P; Venat L; Wierzbicka E; Zattara H
    Br J Cancer; 2008 Jul; 99(2):364-70. PubMed ID: 18612309
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A large de novo 9p21.3 deletion in a girl affected by astrocytoma and multiple melanoma.
    Frigerio S; Disciglio V; Manoukian S; Peissel B; Della Torre G; Maurichi A; Collini P; Pasini B; Gotti G; Ferrari A; Rivoltini L; Massimino M; Rodolfo M
    BMC Med Genet; 2014 May; 15():59. PubMed ID: 24884915
    [TBL] [Abstract][Full Text] [Related]  

  • 14. CDKN2a/p16INK4a mutations and lack of p19ARF involvement in familial melanoma kindreds.
    Fargnoli MC; Chimenti S; Keller G; Soyer HP; Dal Pozzo V; Höfler H; Peris K
    J Invest Dermatol; 1998 Dec; 111(6):1202-6. PubMed ID: 9856841
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Frequent p16-independent inactivation of p14ARF in human melanoma.
    Freedberg DE; Rigas SH; Russak J; Gai W; Kaplow M; Osman I; Turner F; Randerson-Moor JA; Houghton A; Busam K; Timothy Bishop D; Bastian BC; Newton-Bishop JA; Polsky D
    J Natl Cancer Inst; 2008 Jun; 100(11):784-95. PubMed ID: 18505964
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Familial melanoma-astrocytoma syndrome: synchronous diffuse astrocytoma and pleomorphic xanthoastrocytoma in a patient with germline CDKN2A/B deletion and a significant family history.
    Chan AK; Han SJ; Choy W; Beleford D; Aghi MK; Berger MS; Shieh JT; Bollen AW; Perry A; Phillips JJ; Butowski N; Solomon DA
    Clin Neuropathol; 2017; 36(5):213-221. PubMed ID: 28699883
    [TBL] [Abstract][Full Text] [Related]  

  • 17. CDKN2A, CDKN2B and p14ARF are frequently and differentially methylated in ependymal tumours.
    Rousseau E; Ruchoux MM; Scaravilli F; Chapon F; Vinchon M; De Smet C; Godfraind C; Vikkula M
    Neuropathol Appl Neurobiol; 2003 Dec; 29(6):574-83. PubMed ID: 14636164
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Frequent loss of chromosome 9, homozygous CDKN2A/p14(ARF)/CDKN2B deletion and low TSC1 mRNA expression in pleomorphic xanthoastrocytomas.
    Weber RG; Hoischen A; Ehrler M; Zipper P; Kaulich K; Blaschke B; Becker AJ; Weber-Mangal S; Jauch A; Radlwimmer B; Schramm J; Wiestler OD; Lichter P; Reifenberger G
    Oncogene; 2007 Feb; 26(7):1088-97. PubMed ID: 16909113
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Novel and recurrent p14 mutations in Italian familial melanoma.
    Binni F; Antigoni I; De Simone P; Majore S; Silipo V; Crisi A; Amantea A; Pacchiarini D; Castori M; De Bernardo C; Catricalà C; Grammatico P
    Clin Genet; 2010 Jun; 77(6):581-6. PubMed ID: 20132244
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prevalence of 9p21 deletions in UK melanoma families.
    Mistry SH; Taylor C; Randerson-Moor JA; Harland M; Turner F; Barrett JH; Whitaker L; Jenkins RB; Knowles MA; Bishop JA; Bishop DT
    Genes Chromosomes Cancer; 2005 Nov; 44(3):292-300. PubMed ID: 16032697
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.